1 min read
Add as a preferred source on GoogleAnaptysBio Shares Rise After FDA Expands Jemperli Approval
The accelerated approval adds a use for GSK’s cancer treatment in a type of rectal cancer.
AnaptysBio shares rose Monday, Oct. 19, after the U.S. Food and Drug Administration (FDA) expanded approval of GSK’s Jemperli for a type of rectal cancer through its accelerated pathway.
The decision adds a use to the label for Jemperli, an anti-PD-1 cancer treatment. AnaptysBio is GSK’s partner on the drug.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.